Exploring the Therapeutic Potential of TGF-Beta Inhibitors for Liver Fibrosis: Targeting Multiple Signaling Pathways

    July 2025 in “ Journal of Clinical and Translational Hepatology ”
    Wanchun Zhu, Yu Cui, Jun Qiu, Xin Zhang, Yueqiu Gao, Zhi Shang, Lingying Huang
    TLDR TGF-β inhibitors may help treat liver fibrosis by targeting various pathways.
    Liver fibrosis, a precursor to cirrhosis and liver cancer, currently lacks specific drug treatments, with etiological therapy being the primary approach. This review highlights the potential of TGF-β inhibitors as anti-fibrotic agents, emphasizing their ability to reduce liver fibrosis by targeting multiple signaling pathways. The discussion includes the use of active ingredients from Traditional Chinese Medicine, suggesting a promising avenue for developing effective treatments for liver fibrosis.
    Discuss this study in the Community →